Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1613 1645 1654 1658 1675
This examiner grants 33% of resolved cases
Fred H. Reynolds is an examiner in Tech Center 1600, specifically Art Unit 1613, with 842 resolved cases. His allowance rate of 32.9% indicates a rigorous examination environment where a minority of the applications result in a grant. This low baseline rate suggests that practitioners must be prepared for a difficult prosecution path and a high likelihood of initial rejections.
The median days to allowance is 1093, providing a timeline for the applications that do eventually succeed. A critical insight from the data is the interview lift of 39.1%. This significant increase in the probability of allowance following an interview suggests that direct communication is an effective strategy for overcoming the examiner's objections and improving the 32.9% baseline rate.
For the 842 resolved cases, the 39.1% interview lift is a vital statistic for strategy development. The 1093-day median duration underscores the need for persistent effort. Practitioners should prioritize interviews as a primary means of navigating Art Unit 1613, as the data indicates that this examiner is much more likely to grant an application after a direct discussion has taken place.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18279931 | PHOTOCAGED CITRULLINE ANALOGS AND METHODS FOR SITE-SPECIFIC INCORPORATION OF CITRULLINE INTO PROTEINS | Final Rejection | University of Massachusetts |
| 17403357 | COMPOSITIONS COMPRISING A DELIVERY AGENT AND PREPARATION THEREOF | Non-Final OA | Novo Nordisk A/S |
| 18338700 | METHOD FOR PRODUCING PEPTIDE, PROTECTIVE GROUP-FORMING REAGENT, AND CONDENSED POLYCYCLIC COMPOUND | Non-Final OA | FUJIFILM Corporation |
| 18339817 | NOVEL CYCLIC PEPTIDES BASED ON NANOBIOSTRUCTURAL CONTROL, PEPTIDESOMES WITH CORE/SHELL STRUCTURE COMPRISING SAME, AND USES THEREOF | Final Rejection | UIF (University Industry Foundation), Yonsei University |
| 18252069 | METHOD OF SENSITIZING CANCERS TO IMMUNOTHERAPY USING IMMUNOMODULATORY AGENTS | Final Rejection | The Regents of the University of California |
| 17597925 | ANTIMICROBIAL THERAPY THROUGH THE COMBINATION OF PORE-FORMING AGENTS AND HISTONES | Final Rejection | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA |
| 18253231 | PROSTATE-SPECIFIC MEMBRANE ANTIGEN (PSMA)-TARGETED PRODRUG FOR SELECTIVE KILLING OF CELLS EXPRESSING PSMA | Non-Final OA | The Johns Hopkins University |
| 18259092 | METHODS OF TREATING, DIAGNOSING AND PREDICTING PROGNOSIS OF SEPSIS | Non-Final OA | University of Rochester |
| 17633631 | METHODS OF MAKING INCRETIN ANALOGS | Final Rejection | ELI LILLY AND COMPANY |
| 17438692 | PRESERVED FORMULATIONS | Non-Final OA | Eli Lilly and Company |
| 17747952 | SOLID PHASE PEPTIDE SYNTHESIS METHODS AND ASSOCIATED SYSTEMS | Non-Final OA | Massachusetts Institute of Technology |
| 18578343 | IL-2 MUTEINS FOR TREATING CANCER OR INFECTION | Non-Final OA | Merck Sharp & Dohme LLC |
| 17006591 | PROTEASE SENSITIVE GVPC AND RELATED GAS VESICLE GENE CLUSTERS, EXPRESSION SYSTEMS, CONSTRUCTS, VECTORS, GENETIC CIRCUITS, CELLS, COMPOSITIONS, METHODS AND SYSTEMS FOR CONTRAST-ENHANCED IMAGING | Final Rejection | California Institute of Technology |
| 18030876 | PEPTIDE INHIBITORS OF GLIOMA-ASSOCIATED ONCOGENE DERIVED FROM THE COILED-COIL DIMERIZATION DOMAIN OF Kif7 | Non-Final OA | The General Hospital Corporation |
| 18252073 | Peptide Inhibitors of Human Mitochondrial Fission Protein 1 and Methods of Use | Non-Final OA | The Medical College of Wisconsin, Inc. |
| 18567010 | SELECTIVE PENICILLAMINE SUBSTITUTION ENABLES DEVELOPMENT OF A POTENT ANALGESIC PEPTIDE THAT ACTS THROUGH A NON-OPIOID BASED MECHANISM | Non-Final OA | University of Utah Research Foundation |
| 17608025 | METHODS AND COMPOSITIONS INVOLVING TERT ACTIVATING THERAPIES | Final Rejection | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM |
| 17586258 | MUTANTS AND DRUG CONJUGATES OF R-SPONDINS AND USE THEREOF | Final Rejection | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM |
| 17788506 | METHOD FOR SYNTHESIZING PEPTIDE COMPOUND | Non-Final OA | CHUGAI SEIYAKU KABUSHIKI KAISHA |
| 18561384 | PEPTIDE DRUG CONJUGATES SPECIFIC TO FIBRONECTIN ISOTYPES FOR CANCER THERAPY | Non-Final OA | Case Western Reserve University |
| 17918448 | GUANIDINE-MODIFIED C-TERMINUS VANCOMYCIN COMPOUNDS, COMPOSITIONS AND METHODS | Final Rejection | THE SCRIPPS RESEARCH INSTITUTE |
| 17413223 | COMPOSITIONS AND METHODS FOR THE DELIVERY OF THERAPEUTIC AGENTS ACROSS THE ROUND WINDOW MEMBRANE | Non-Final OA | Decibel Therapeutics, Inc. |
| 17251079 | NON-VITAL WHEAT PROTEIN AND ITS PRODUCTION PROCESS | Final Rejection | ROQUETTE FRERES |
| 18728991 | GEPOTIDACIN AND VANCOMYCIN FOR USE IN THE TREATMENT OF AN INFECTION CAUSED BY STAPHYLOCOCCUS SAPROPHYTICUS | Non-Final OA | GlaxoSmithKline Intellectual Property Development Limited |
| 18126270 | POLYMYXIN DERIVATIVES AND THEIR USE IN COMBINATION THERAPY TOGETHER WITH DIFFERENT ANTIBIOTICS | Final Rejection | SPERO THERAPEUTICS, INC. |
| 18282160 | NOVEL BICYCLIC COMPOUND, OPTICAL ISOMER THEREOF OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, USE THEREOF, AND PREPARATION METHOD THEREFOR | Non-Final OA | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY |
| 18312110 | NOVEL PEPTIDE HAVING ANTI-INFLAMMATORY AND TISSUE REGENERATIVE ACTIONS | Final Rejection | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY |
| 18682498 | FILMS FORMED FROM SELF-ASSEMBLING PEPTIDE HYDROGELS | Non-Final OA | GEL4MED, INC. |
| 18563552 | Multi-Agonist and Use Thereof | Final Rejection | The United Bio-Technology (Hengqin) Co., Ltd |
| 17766250 | COMPOSITIONS COMPRISING PEDF-DERIVED SHORT PEPTIDES (PDSP) AND USES THEREOF | Final Rejection | BRIM Biotechnology, Inc. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy